Inflectra becomes first FDA-approved biosimilar for inflammatory diseasesApril 5, 2016Rheumatoid ArthritisAnkylosing spondylitisPsoriatic ArthritisSpondyloarthropathies
Pushback on Part B drug payment proposal already beginningMarch 22, 2016Rheumatoid ArthritisAnkylosing spondylitisPsoriatic ArthritisLupus & Connective Tissue DiseasesPediatricsSpondyloarthropathiesBusiness of Medicine
Home infusion policies called out in ACR position statementMarch 22, 2016Rheumatoid ArthritisLupus & Connective Tissue DiseasesPediatricsSpondyloarthropathiesAnkylosing spondylitisPsoriatic Arthritis
ACR’s 2016-2020 research agenda built through consensusMarch 18, 2016Rheumatoid ArthritisAnkylosing spondylitisPsoriatic ArthritisSpondyloarthropathiesGoutLupus & Connective Tissue DiseasesOrthopedics
Sparse, poor evidence supports fumarates for psoriasisMarch 15, 2016SpondyloarthropathiesPsoriatic Arthritis
Anti-Remicade antibodies also cross-react with infliximab biosimilarMarch 14, 2016Rheumatoid ArthritisAnkylosing spondylitisPsoriatic ArthritisSpondyloarthropathies
Fresh evidence of methotrexate efficacy in psoriatic arthritisMarch 13, 2016Psoriatic ArthritisSpondyloarthropathies
Don’t overlook topical tazarotene for psoriasisMarch 10, 2016SpondyloarthropathiesPsoriatic Arthritis
60 weeks of ixekizumab effective, well tolerated in moderate-to-severe plaque psoriasisMarch 10, 2016Psoriatic ArthritisSpondyloarthropathies
Minimal disease activity criteria in PsA fall shortMarch 9, 2016Psoriatic ArthritisSpondyloarthropathies
Brodalumab met primary endpoints, deaths called ‘unrelated’March 7, 2016SpondyloarthropathiesPsoriatic Arthritis
